Skip to main content

NCCIH Clinical Trial Notice of Funding Opportunities—Applicant FAQs

1. Why does NCCIH offer separate clinical trial funding opportunities for mechanistic studies and clinical outcome studies?

NCCIH recognizes a difference between clinical trials that are designed to answer specific questions about the clinical effect(s) of interventions and mechanistic studies that have the primary goal of understanding how an intervention works.

  • A clinical outcome study is defined as one with the objective of determining the clinical safety, tolerability, feasibility, efficacy, and/or effectiveness of pharmacologic, nonpharmacologic, behavioral, biologic, surgical, or device (invasive or noninvasive) interventions.
  • A mechanistic study is defined as one designed to understand the mechanism of action of an intervention, a biological or behavioral process, or the pathophysiology of a disease.
  • NCCIH has created a suite of separate clinical trial funding opportunities to support mechanistic research focused on understanding how a mind and body or natural product intervention works, and to support clinical research to develop and test the feasibility, efficacy, and effectiveness of mind and body or natural product interventions for particular conditions. We encourage investigators to choose which research question they wish to focus on first: “How Does This Intervention Work?” or “Does This Intervention Work for a Given Condition?" Investigators can then select an appropriate funding opportunity.

If you’re not sure which funding opportunity best suits your research, please contact or the appropriate NCCIH program director that aligns with your research topic/question(s).

2. What types of research do NCCIH clinical trial funding opportunities support?

NCCIH Clinical Trial funding opportunities fund investigator-initiated natural product studies and mind and body intervention studies, and they are designed to support all phases of clinical intervention development and testing.
In addition to funding fully powered efficacy or effectiveness trials, we support investigators working to establish “building blocks” that bridge the gap from basic research to high-impact clinical trials on complementary and integrative health interventions. Examples of building blocks include feasibility testing, assessment of outcome measures, and intervention fidelity testing. Since it’s often difficult for investigators to find research funding to establish these building blocks, we provide funding mechanisms for these foundational components. NCCIH also funds multisite clinical trials to assess the efficacy or effectiveness of a complementary or integrative health intervention.

3. What kinds of human subjects research will NCCIH still accept through the Parent R01?

The National Institutes of Health (NIH) now offers three options for the Parent R01 (see comparison of funding opportunity types by clinical trial allowability):

  • Parent R01 Clinical Trial Not Allowed (PA-20-185): NCCIH will continue to accept applications to this funding opportunity for observational studies such as survey studies, cohort studies, or case-control studies, as well as secondary analyses of existing data sets or banked samples.
  • Parent R01 Clinical Trial Required (PA-20-183): NCCIH will only accept applications that propose human mechanistic trials/studies (see NOT-AT-20-001); no applications will be accepted that include any specific aims that propose to assess efficacy or effectiveness of any intervention, unless otherwise noted in a Notice of Special Interest.
  • Parent R01 Basic Experimental Studies With Humans Required (PA-20-184): NCCIH will accept applications that propose basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application toward processes or products in mind.
If you aren’t sure which funding mechanism to use, please contact or the appropriate NCCIH program director that aligns with your research topic/question(s).

4. I want to apply for funding to further analyze an existing clinical trial database to address questions that are beyond those addressed in the planned primary analyses of the trial. Could I use a Parent R01 Notice of Funding Opportunity? Which one?

Yes. Because you do not plan to enroll new participants and will not be recontacting study participants, you could use the Parent R01 Clinical Trial Not Allowed Notice of Funding Opportunity (PA-20-185).

5. I want to apply for funding to conduct a prospective observational study of patients being treated in real-life practice settings. Could I use a Parent R01 Notice of Funding Opportunity? Which one?

Yes. Because the participants are not assigned to a treatment as part of this observational study, you could use the Parent R01 Clinical Trial Not Allowed Notice of Funding Opportunity (PA-20-185).

6. What will happen to my application if I submit a clinical trial focused on clinical outcomes to the Parent R01 (Clinical Trial Required) and ask for it to be assigned to NCCIH?

NCCIH won’t accept your application (see NOT-AT-20-001). The Center for Scientific Review (CSR) might be able to find another Institute or Center (IC) at NIH to accept it, but if other ICs won’t accept it because it doesn't align with their research priorities, the application will be withdrawn without review. To avoid this possibility, it is recommended that applicants contact NCCIH program directors for advice prior to submission and use the NCCIH clinical trial–specific funding opportunities when appropriate.

7. What’s different about the NCCIH-issued clinical trial funding opportunities?

The NCCIH funding opportunities are specifically designed for investigator-initiated clinical trials on complementary and integrative approaches.

  • Applicants using the funding opportunities must provide details about their proposed clinical studies in a standardized way via the “PHS Human Subjects and Clinical Trials Information” form in the application package. (PHS stands for Public Health Service.)
  • The NCCIH clinical trial funding opportunities also require additional attachments depending on each funding opportunity. These attachments may include a Clinical Trial Experience Table, a Milestone Plan, and/or a Project Management Plan. Please check for “Related Notices” in the funding opportunities detailing any changes to required elements.
  • NCCIH special review panels will use the information in the PHS Human Subjects and Clinical Trials Information form and the additional attachments to assess key elements of the clinical study, investigator experience, and how regulatory issues will be addressed.

8. How do I decide if NCCIH is the best fit for my proposal vs. other NIH ICs?

We strongly encourage you to review the NCCIH strategic plan, including the top scientific priority areas listed in the plan, to see if your research interests align with the Center’s. You may also review the Center’s active funding announcements for any funding opportunities of interest. If NCCIH is one of several NIH components that has signed on to a funding opportunity, pay attention to statements about our Center’s research interests. Also, look for NIH Guide Notices listed in the funding opportunity itself.
We encourage you to contact the NCCIH program director listed in the funding announcement to discuss your potential application. It may facilitate the conversation if you send a short summary of the specific aims of your study.

9. How do I decide which funding opportunity to apply for?

NCCIH has developed separate independent clinical trial funding opportunities for (1) natural product studies and (2) studies of mind and body interventions, so be sure you’re looking at the series best suited for your area of research. If you are proposing research on multicomponent or integrative interventions, apply to the mind and body series.
Then, within that series, choose the funding opportunity that most closely matches the stage of research that your project represents. Each series includes funding opportunities for early-phase trials, intermediate trials, and full-scale efficacy, effectiveness, or pragmatic trials. Each funding opportunity describes what type of preliminary data is needed for the stage of research that the funding opportunity supports.
If you’re not sure which funding opportunity is most suitable for your research, please contact or the appropriate NCCIH program director that aligns with your research topic/question(s).

10. Who will review applications submitted in response to NCCIH clinical trial funding opportunities?

Applications submitted to the Notice of Special Interest in Fundamental Science Research on Complementary and Integrative Health Approaches, including natural products or mind and body interventions, via the Parent R01 and R21 Notices of Funding Opportunities (NOT-AT-21-006), are reviewed by standing study sections in the NIH Center of Scientific Review. Most applications to other NCCIH clinical trial funding opportunities will be reviewed by NCCIH special review panels with expertise in both clinical trials and complementary health approaches. The panels will include experts familiar with the unique challenges faced by this research community. Panel members also provide valuable advice to NCCIH and constructive feedback to investigators.

11. What is the difference between an RFA (Request for Applications - Grants) and PA/PAR/PAS (Program Announcement/Program Announcement Reviewed by a Specific Institute)?

A PA/PAR/PAS is an ongoing solicitation, usually with multiple receipt dates. A PAR is a PA with special receipt, referral, and/or review considerations. A PAS is a PA that includes specific set-aside funds. RFAs are solicitations in a well-defined scientific area to achieve specific program objectives. RFAs usually have a single receipt date, are reviewed by a review group convened only for that RFA, and have set-aside funds for awarding grants.
Please contact the appropriate NCCIH program director to ensure your proposed study is within NCCIH priorities before preparing an application.

12. Are there additional review criteria that will affect my proposal's scores and prospects for funding?

Yes. Applicants are strongly encouraged to pay close attention to the review criteria in the funding opportunity. Investigators must include all requested information and address the specific review criteria listed in the funding opportunity. Review criteria will impact the scoring of the application.

13. I’ve heard that applications may be returned without review if they don't contain the required elements or aren't compliant with the funding annoucement instructions. Is this true, and how can I be sure that my application is complete and compliant?

Yes. It’s standard procedure at NIH to review applications for completeness. The NCCIH clinical trial funding opportunities describe attachments and information that must be included for your application to be considered responsive and complete. If your application does not include these required elements, it will be returned to the submitting institution. Please check for “Related Notices” in the funding opportunity in case there are any changes to required elements.
In addition, the funding opportunities indicate what stage of research will be supported by each funding opportunity. Each funding opportunity provides a list of clinical trials that are not responsive to that specific funding opportunity. If your proposed trial is not responsive to the funding opportunity (for example, if you submit an application for an efficacy trial to an early-phase clinical research funding opportunity), your application will be deemed nonresponsive and will not be reviewed.

14. What materials can be included in an appendix of an NCCIH clinical trial application?

Nearly all of NCCIH’s clinical trial funding opportunities require additional attachments, including an additional three pages for a table of all study investigators’ experience conducting clinical trials. Additional items are required for multisite trials. Please see the instruction section of the funding opportunity you plan to use for further details.
NCCIH follows the NIH policy for standard materials that are allowed in the appendix (NOT-OD-18-126).

15. Are multisite trials allowed?

Yes, the UG3/UH3 funding opportunities encourage the submission of multisite trials to assess efficacy and effectiveness of complementary health approaches, and the NCCIH R01 funding opportunities also allow multisite studies. Please discuss your proposed trial with the appropriate NCCIH program director before submitting your application.
All UG3/UH3 clinical trial proposals require the submission of a companion data coordinating center application (U24). Current examples: (PAR-AT-21-242) (PAR-AT-21-243)

16. Are multisite trials expected to have a single Institutional Review Board (IRB)? Who will organize a single IRB?

NIH issued a policy in 2016 that establishes the expectation that a single IRB of record will be used for multisite research. You can find an introduction to this policy on NCCIH’s Research Blog and the full policy on NIH’s website. Information on special exceptions to the single IRB rule in studies involving U.S. Department of Veterans Affairs and U.S. Department of Defense sites can also be found here.

17. Will NCCIH be taking a more active role as a collaborator in my research?

For cooperative agreement mechanisms (i.e., U awards), once an award has been made, an NCCIH staff member will be assigned as a program scientist and participate in the steering committee for it. This person will serve as a resource for the study team.
NCCIH staff know of the challenges presented by complementary and integrative health research and are available to help grantees address these challenges. The NCCIH Clinical Research Toolbox is an example of one resource we have developed to assist investigators.

18. Is it necessary to register all clinical trials with

19. Is data sharing encouraged?

Yes. In some cases, data sharing is required as part of the funding opportunity or by NIH policies (like the NIH Genomic Data Sharing Policy). Please contact an NCCIH program director for details.

20. Is a recruitment plan required? Will NCCIH monitor progress of the trial? Are there consequences for failing to meet the recruitment milestones?

Yes, yes, and yes. Please consult NCCIH’s policy on Study Accrual and Retention for Human Subject Research for details. This policy provides transparency on how NCCIH carries out oversight of study accrual and retention. Corrective actions, up to and including cessation of recruitment for a study, are outlined in this policy.

21. What is a Data Safety and Monitoring Plan?

A complete description can be found on the NCCIH website: Data and Safety Monitoring of NCCIH-Funded Clinical Research. The website includes sample templates that applicants may use.

22. How does an applicant decide what the appropriate level of data and safety oversight is?

You can learn more from the documents in NCCIH’s Clinical Research Toolbox and from NCCIH's policy on Data and Safety Monitoring of NCCIH-Funded Clinical Research.
NCCIH requires independent monitoring of all human subjects research. A Data and Safety Monitoring Board is required for all Phase III trials and should be considered for other clinical trials with elevated safety risks.

23. I received a good score on my clinical trial application at another IC, but they aren’t going to fund it. My research includes a complementary health intervention. Can my application be transferred to NCCIH?

In some cases, NIH applications can be transferred from one IC to another. NCCIH must be a participating component on the funding opportunity for which the application was submitted for NCCIH to accept transfer. Additionally, the NIH IC that accepted your application must be willing to allow transfer of the application to NCCIH. Applicants are encouraged to begin this conversation with the program official assigned to the application before contacting NCCIH.

24. How many Clinical Trial Experience Tables am I required to include? Can I submit a table for each key personnel?

One table must be provided that includes all key personnel, and it must not exceed three pages. If your application includes more than one clinical trial (i.e., more than one study record), you may submit one table per study record with a unique filename for each study record as an attachment (e.g., “Clinical Trial Experience1.pdf”, “Clinical Trial Experience 2.pdf”). For two or more study records, it will be helpful to include more than one Clinical Trial Experience Table if key personnel for each trial (i.e., study record) includes different individuals.

25. Should I only include those clinical trials in the table where all the key personnel have collaborated in the past?

The Clinical Trial Experience Table does not have to be collaborative (i.e., you could list trials that a single key person worked on and others were not involved in), but you are only allowed one table to summarize the experience of all key personnel involved.

26. How many years of experience should I report in the Clinical Trial Experience Table?

The Clinical Trial Experience Table should demonstrate experience of key personnel in clinical trial conduct/coordination in the last 5 years.

27. What information should be included in the Milestones plan? Is there a template for the Milestone Plan that I could follow?

The Milestone Plan should describe the key milestones that you need to be meet throughout the lifecycle of the clinical trial to ensure its success. The processes that will be used to reach the milestones and a timetable identifying when each of these key milestones will be met need to be included in the plan. Some samples for milestones can be found in the NCCIH Clinical Trials Toolbox

Please contact the appropriate NCCIH program director to ensure your proposed study is within NCCIH priorities before preparing an application.